Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.

Jain S, Shahane A, Derk CT.

Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):266-77. Review.

PMID:
22506881
2.

Progressive systemic sclerosis and the lung.

Veeraraghavan S, Sharma OP.

Curr Opin Pulm Med. 1998 Sep;4(5):305-9. Review.

PMID:
10813207
3.

Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

Fathi N, Furst DE, Clements PJ.

Curr Rheumatol Rep. 2007 May;9(2):144-50.

PMID:
17502045
4.

[Interstitial lung disease in systemic sclerosis].

Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D.

Rev Mal Respir. 2007 Oct;24(8):1035-46. Review. French.

5.

Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.

Tan A, Denton CP, Mikhailidis DP, Seifalian AM.

Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S66-74. Epub 2011 May 13. Review.

PMID:
21586221
6.

Targeted therapy for systemic sclerosis.

Steen V.

Autoimmun Rev. 2006 Feb;5(2):122-4. Epub 2005 Sep 21. Review.

PMID:
16431341
7.

Pulmonary complications: one of the most challenging complications of systemic sclerosis.

Wells AU, Steen V, Valentini G.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii40-4. doi: 10.1093/rheumatology/kep109. Review.

PMID:
19487223
8.
9.

Scleroderma lung: pathogenesis, evaluation and current therapy.

van Laar JM, Stolk J, Tyndall A.

Drugs. 2007;67(7):985-96. Review.

PMID:
17488144
10.

The evolving pharmacotherapy of pulmonary fibrosis.

Lota HK, Wells AU.

Expert Opin Pharmacother. 2013 Jan;14(1):79-89. doi: 10.1517/14656566.2013.758250. Review.

PMID:
23265249
11.

Treatment of complications associated with systemic sclerosis.

Moore SC, Desantis ER.

Am J Health Syst Pharm. 2008 Feb 15;65(4):315-21. doi: 10.2146/ajhp070024. Review.

PMID:
18238768
12.

Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.

Vallance DK, Lynch JP 3rd, McCune WJ.

Curr Opin Rheumatol. 1995 May;7(3):174-82. Review.

PMID:
7612408
13.

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

Clin Rheumatol. 2007 Feb;26(2):168-72. Epub 2006 Apr 14.

PMID:
16614793
14.

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V.

Rheumatology (Oxford). 2009 Jan;48(1):49-52. doi: 10.1093/rheumatology/ken369. Epub 2008 Sep 24.

PMID:
18815156
15.

Therapeutic options for systemic sclerosis related interstitial lung diseases.

Mouthon L, Bérezné A, Guillevin L, Valeyre D.

Respir Med. 2010 Jul;104 Suppl 1:S59-69. doi: 10.1016/j.rmed.2010.03.018.

16.

New therapeutic strategies in the management of systemic sclerosis.

Allanore Y, Avouac J, Wipff J, Kahan A.

Expert Opin Pharmacother. 2007 Apr;8(5):607-15. Review.

PMID:
17376016
17.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442
18.

Emerging targeted therapies in scleroderma lung and skin fibrosis.

Maurer B, Distler O.

Best Pract Res Clin Rheumatol. 2011 Dec;25(6):843-58. doi: 10.1016/j.berh.2011.11.007. Review.

PMID:
22265265
19.

An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis.

Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E, Rosen G, Chung L.

J Rheumatol. 2011 Apr;38(4):693-701. doi: 10.3899/jrheum.100675. Epub 2011 Feb 1.

PMID:
21285162
20.

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP.

Curr Rheumatol Rep. 2009 Apr;11(2):111-9. Review.

PMID:
19296883

Supplemental Content

Support Center